• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

BNT162b2 vaccination after SARS-CoV-2 infection decreases risk of recurrent infection

byBoaz WongandHarsh Shah
May 9, 2022
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In a retrospective cohort study of individuals who recovered from SARS-CoV-2, BNT162b2 vaccination decreased the risk of recurrent infection.

Evidence Rating Level: 2 (Good)

Study Rundown: The long-term effectiveness and durability of immune protection provided after SARS-CoV-2 (Covid-19) infection are unclear. The purpose of this retrospective cohort study was to evaluate whether vaccination by the BNT162b2 Covid-19 (Pfizer-BioNTech) vaccine would protect against reinfection in individuals previously infected with Covid-19. In this retrospective cohort study, the electronic medical records of patients who had previously recovered from Covid-19 in Israel were reviewed for incidence of reinfection. Reinfection rates between individuals vaccinated with the BNT162b2 vaccine and unvaccinated individuals were compared to determine vaccine effectiveness. The study found that reinfection occurred in 2.46 cases per 100,000 persons per day in vaccinated individuals which were significantly lower compared to 10.21 cases per 100,000 persons per day amongst unvaccinated individuals, resulting in 82% vaccine effectiveness. Rates were similar between individuals vaccinated with one dose compared to those receiving two doses. Taken together, this study supports that previously infected individuals who also receive subsequent vaccination against Covid-19 are at lower risk for reinfection compared to those who are unvaccinated. The findings of this study are limited by the retrospective design of the study, reliance on irregular PCR testing, and analysis only of patients receiving the BNT162b2 vaccine.

Click to read the study in NEJM 

Relevant Reading: mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

In-Depth [retrospective cohort]: In this retrospective cohort study, 149,032 electronic medical records of individuals previously infected with SARS-CoV-2 (Covid-19) in a single healthcare center in Israel were reviewed. Patients were eligible if they had recovered from documented Covid-19 infection 100 days before receipt of any vaccination and did not already experience Covid-19 reinfection. The study cohort was divided into those receiving at least one dose of BNT162b2 Covid-19 vaccine and unvaccinated with the primary outcome being the incidence of Covid-19 reinfection as determined by polymerase chain reaction (PCR) testing. The Cox proportional-hazards regression model was used to analyze statistical differences between the two groups. Reinfections were significantly lower in the vaccinated group where 354 of 83,356 individuals were reinfected (2.46 cases per 100,000 persons per day), compared to the unvaccinated group where 2,120 of 60,877 patients experienced reinfection (10.79 cases per 100,000 persons per day). The adjusted hazard ratio for protection against reinfection by vaccination was 0.18 (95% Confidence Interval [CI], 0.16-0.20) in patients between 16- 64 years old, and 0.40 (95% CI, 0.24-0.64) for those over 65. The vaccine effectiveness was estimated to be 82% (95% CI, 80-84). Reinfection rates were similar among individuals with a hazard ratio of 0.98 (95% CI, 0.64-1.5) for individuals receiving two doses compared to one dose. Overall, the study supports that vaccination with the BNT162b2 vaccine confers significant protection against Covid-19 reinfection in those already previously infected with Covid-19.

Image: PD

RELATED REPORTS

Awake prone positioning does not seem to offer benefit in reducing endotracheal intubation for COVID-19-induced acute respiratory failure: COVI-PRONE trial

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bnt162b2coronarvirusCOVID-19COVID-19 VaccineSARS-CoV-2
Previous Post

Weight loss and lifestyle interventions significantly decrease obstructive sleep apnea severity

Next Post

Protection against SARS-CoV-2 highest after infection-acquired immunity boosted with vaccination in health care workers

RelatedReports

Novel coronavirus identified from patients with pneumonia in Wuhan, China
Emergency

Awake prone positioning does not seem to offer benefit in reducing endotracheal intubation for COVID-19-induced acute respiratory failure: COVI-PRONE trial

May 16, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

May 13, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

May 13, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

BNT162b2 safe and efficacious in children 5 to 11 years of age

May 13, 2022
Next Post
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Protection against SARS-CoV-2 highest after infection-acquired immunity boosted with vaccination in health care workers

Patient Basics: Urinary Incontinence

Single-incision mini-slings effective for urinary incontinence in women

Dacomitinib may be effective in EGFR-associated lung cancer

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Adebrelimab plus chemotherapy improves overall survival in extensive-stage small-cell lung cancer
  • Tiragolumab with atezolizumab is a promising treatment option for PD-L1 positive advanced non-small-cell-lung cancer
  • University students perceive that Instagram improves social connection but impairs mental wellbeing
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.